What does this research mean for the field?

SGLT2 inhibitors provide significant extraglycemic benefits, most notably cardiorenal protection, through a combination of canonical renal mechanisms and emerging non-canonical pathways that operate independently of glucose lowering. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To review canonical renal mechanisms, compound-specific pharmacology, and emerging non-canonical pathways mediating the extraglycemic effects of SGLT2 inhibitors.

August 23, 2026Cell Biology and ToxicologyOpen Access

Pleiotropic effects of SGLT2 inhibitors beyond diabetes

View Full Paper

Ask AI

Bookmark

Authors

RJRui Ji BDBinbin Dai ZLZikang Liu

Discussion

Member takes

Overview

Systematic review uncovers diverse cardiorenal and cellular actions of SGLT2 inhibitors in diabetic and non-diabetic settings, highlighting pathways beyond glycemic control.

Key Points

To review canonical renal mechanisms, compound-specific pharmacology, and emerging non-canonical pathways mediating the extraglycemic effects of SGLT2 inhibitors.
Synthesized molecular, preclinical, multi-omic (transcriptomics, proteomics, metabolomics), and clinical trial evidence.
Evaluated transporter-independent actions, ion handling, mitochondrial energetics, and inflammatory signaling across cardiorenal, neurocognitive, and oncologic settings.
Clinical evidence strongly establishes cardiorenal protective benefits, with emerging but less definitive data for neurocognitive and anticancer applications.
Extraglycemic mechanisms operate partly independent of glucose lowering through metabolic remodeling, improved mitochondrial function, altered ion homeostasis, and attenuated inflammation.

Cite This Study

Ji et al. (2026) studied this question.

synapsesocial.com/papers/6a8aae337677a34114446fb0 https://doi.org/10.1007/s10565-026-10258-0

View Full Paper

Ask AI

Bookmark

August 23, 2026Cell Biology and ToxicologyOpen Access

Pleiotropic effects of SGLT2 inhibitors beyond diabetes

View Full Paper

Ask AI

Bookmark

Authors

RJRui Ji BDBinbin Dai ZLZikang Liu

Discussion

Member takes

Overview

Systematic review uncovers diverse cardiorenal and cellular actions of SGLT2 inhibitors in diabetic and non-diabetic settings, highlighting pathways beyond glycemic control.

Key Points

To review canonical renal mechanisms, compound-specific pharmacology, and emerging non-canonical pathways mediating the extraglycemic effects of SGLT2 inhibitors.
Synthesized molecular, preclinical, multi-omic (transcriptomics, proteomics, metabolomics), and clinical trial evidence.
Evaluated transporter-independent actions, ion handling, mitochondrial energetics, and inflammatory signaling across cardiorenal, neurocognitive, and oncologic settings.
Clinical evidence strongly establishes cardiorenal protective benefits, with emerging but less definitive data for neurocognitive and anticancer applications.
Extraglycemic mechanisms operate partly independent of glucose lowering through metabolic remodeling, improved mitochondrial function, altered ion homeostasis, and attenuated inflammation.

Cite This Study

Ji et al. (2026) studied this question.

synapsesocial.com/papers/6a8aae337677a34114446fb0 https://doi.org/10.1007/s10565-026-10258-0

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark